<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00185302</url>
  </required_header>
  <id_info>
    <org_study_id>91410</org_study_id>
    <secondary_id>2004-002395-41</secondary_id>
    <secondary_id>309100</secondary_id>
    <nct_id>NCT00185302</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of a New Chemotherapy Agent to Treat Metastatic Melanoma</brief_title>
  <official_title>Phase II Study of MS-275, a Histone Deacetylase Inhibitor, Comparing 2 Dosage Schedules in Patients With Metastatic Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objective: To evaluate the efficacy of two different dosing schedules of MS-275 in
      subjects with metastatic melanoma Secondary objectives: To evaluate the safety and to assess
      the pharmacokinetic profile of MS-275 in subjects with metastatic melanoma
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been
      renamed to Bayer Schering Pharma AG, Germany.Bayer Schering Pharma AG, Germany is the sponsor
      of the trial.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2004</start_date>
  <completion_date type="Actual">July 2006</completion_date>
  <primary_completion_date type="Actual">July 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall tumor response rate (the proportion of subjects with the best tumor response of PR or CR within the first 6 cycles of treatment)</measure>
    <time_frame>Baseline, 8, 16, 24, 32 weeks (cycle 6)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to tumor progression</measure>
    <time_frame>Baseline, every 8 weeks until progression</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>At 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response rate at each tumor assessment time point (CR/PR/SD/PD/not assessable)</measure>
    <time_frame>At baseline and repeated every 2 cycles until tumor progression between Day 22 of even numbered cycles and Day 1 of subsequent odd numbered cycle and also at EOT and F-up visiit (90 days after the EOT and every 3 months until disease progression)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to death</measure>
    <time_frame>Baseline, every 8 weeks until death</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>Approximately 8-64 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>Histone Deacetylase Inhibitor, 3 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received 3 mg MS-275 orally biweekly (Days 1 and 15 of a 4 week cycle) or until disease progression or unacceptable toxicity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Histone Deacetylase Inhibitor, 7 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received 7 mg MS-275 orally weekly (Days 1, 8, and 15 of a 4 week cycle) until disease progression or unacceptable toxicity</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Histone Deacetylase Inhibitor, MS-275 (BAY 86-5274, ZK 244894)</intervention_name>
    <description>MS-275, 3 mg on Days 1 and 15 of a 4-week cycle</description>
    <arm_group_label>Histone Deacetylase Inhibitor, 3 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Histone Deacetylase Inhibitor, MS-275 (BAY 86-5274, ZK 244894)</intervention_name>
    <description>MS-275, 7 mg on Days 1, 8 and 15 of a 4-week cycle</description>
    <arm_group_label>Histone Deacetylase Inhibitor, 7 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult subjects with Stage III or IV non-resectable nonuveal (cutaneous or mucosal)
             metastatic melanoma who had received at least one but no more than two previous
             systemic therapies (immunotherapy and/or chemotherapy) for metastatic disease and who
             had not responded to or who had progressed after their most recent therapy were
             eligible for enrollment

          -  Presence of at least one lesion fulfilling the minimum Response Evaluation Criteria in
             Solid Tumors (RECIST) size requirements for a target lesion - Use of highly effective
             birth control methods in females of child-bearing potential

          -  Able to undergo either contrast enhanced computed tomography (CT) scan or contrast
             enhanced magnetic resonance imaging (MRI) scan for tumor assessment

          -  Life expectancy greater than 3 months

          -  Adequate organ and bone marrow functions as defined below: absolute neutrophil count ≥
             1500 /µL, platelets ≥ 100,000 /µL, creatinine ≤ 1.5 × upper limit of normal (ULN) or
             measured creatinine clearance of ≥ 60 mL/min x 1.73 m2 body surface area, total
             bilirubin ≤ 1.5 times ULN, aspartate aminotransferase or serum glutamic oxalacetic
             transaminase/alanine aminotransferase or serum glutamic pyruvic transaminase∗ ≤ 2.5
             times ULN

          -  Negative serum pregnancy test within 2 weeks prior to receiving the first dose of
             study drug in female subjects of childbearing potential. Agreement to use a highly
             effective method of birth control throughout the study period and 3 months thereafter
             for sexually active males and females of childbearing potentia

        Exclusion Criteria:

          -  Active malignancy in the last five years

          -  Pregnancy, breast feeding

          -  HIV infection

          -  Brain metastasis

          -  Concomitant use of corticosteroids or valproic acid

          -  Uncontrolled intercurrent illness

          -  Diagnosis of uveal melanoma

          -  Eastern Cooperative Oncology Group performance status ≥ 2

          -  Ongoing effects from previous investigational drug studies or concomitant
             participation in other investigational drug studies

          -  Prior use of MS-275 or any other HDAC inhibitor

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to MS-275

          -  Anticancer therapy

          -  Active gastrointestinal conditions that might predispose for poor drug absorption

          -  Major surgery within 4 weeks prior to enrollment

          -  Hypophosphatemia &lt; 2.5 mg/dL at screening, if not corrected in the screening period

          -  Medical, psychiatric or other conditions that compromise the patient's ability to
             understand the patient information, to give informed consent, to comply with the trial
             protocol, or to complete the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <link>
    <url>http://www.bayerpharma.com/en/research-and-development/clinical-trials/trial-finder/index.php</url>
    <description>Click here to find results for studies related to Bayer Healthcare products.</description>
  </link>
  <link>
    <url>http://www.clinicaltrialsregister.eu/</url>
    <description>Click here to find information about studies related to Bayer Healthcare products conducted in Europe.</description>
  </link>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2005</study_first_posted>
  <last_update_submitted>December 10, 2015</last_update_submitted>
  <last_update_submitted_qc>December 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-resectable metastatic melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Histone Deacetylase Inhibitors</mesh_term>
    <mesh_term>Entinostat</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

